.jpg)
ENTX_001 (red) is shown co-localizing with intracellular M. abscessus (green) over time while selectively phagocytosing surrounding macrophages. The proprietary drug delivery mechanism allows for the drug to specifically target intracellular infected macrophages.
Our drug components are synergistic with all standard-of-care (SoC) drugs used to treat NTM. Our drugs acts directly on the mycobacterial envelope therefore not inhibiting the action of other small molecule therapies.
